UroGen Pharma Ltd (NASDAQ: URGN)’s stock price has decreased by -25.79 compared to its previous closing price of 9.85. However, the company has seen a -29.58% decrease in its stock price over the last five trading sessions. businesswire.com reported 2025-05-16 that LOS ANGELES–(BUSINESS WIRE)–The Law Offices of Frank R. Cruz announces an investigation of UroGen Pharma Ltd. (“UroGen” or the “Company”) (NASDAQ: URGN) on behalf of investors concerning the Company’s possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON UROGEN PHARMA LTD. (URGN), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR LOSS. What Is The Investigation About? On May 16, 2025, the U.S. Food and Drug Administration (“FDA”) publi.
Is It Worth Investing in UroGen Pharma Ltd (NASDAQ: URGN) Right Now?
The 36-month beta value for URGN is at 0.59. Analysts have varying views on the stock, with 5 analysts rating it as a “buy,” 2 rating it as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for URGN is 38.22M, and currently, shorts hold a 13.12% of that float. The average trading volume for URGN on May 19, 2025 was 544.91K shares.
URGN’s Market Performance
The stock of UroGen Pharma Ltd (URGN) has seen a -29.58% decrease in the past week, with a -29.64% drop in the past month, and a -32.13% fall in the past quarter. The volatility ratio for the week is 17.33%, and the volatility levels for the past 30 days are at 10.39% for URGN. The simple moving average for the past 20 days is -29.23% for URGN’s stock, with a -37.83% simple moving average for the past 200 days.
Analysts’ Opinion of URGN
Many brokerage firms have already submitted their reports for URGN stocks, with Scotiabank repeating the rating for URGN by listing it as a “Sector Outperform.” The predicted price for URGN in the upcoming period, according to Scotiabank is $23 based on the research report published on April 16, 2025 of the current year 2025.
Ladenburg Thalmann, on the other hand, stated in their research note that they expect to see URGN reach a price target of $31. The rating they have provided for URGN stocks is “Buy” according to the report published on February 19th, 2025.
Guggenheim gave a rating of “Buy” to URGN, setting the target price at $40 in the report published on August 22nd of the previous year.
URGN Trading at -31.10% from the 50-Day Moving Average
After a stumble in the market that brought URGN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -64.69% of loss for the given period.
Volatility was left at 10.39%, however, over the last 30 days, the volatility rate increased by 17.33%, as shares sank -24.41% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -28.26% lower at present.
During the last 5 trading sessions, URGN fell by -29.58%, which changed the moving average for the period of 200-days by -53.38% in comparison to the 20-day moving average, which settled at $10.33. In addition, UroGen Pharma Ltd saw -31.36% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at URGN starting from Schoenberg Mark, who sale 4,551 shares at the price of $11.14 back on Jan 31 ’25. After this action, Schoenberg Mark now owns 145,666 shares of UroGen Pharma Ltd, valued at $50,698 using the latest closing price.
Smith Jason Drew, the General Counsel of UroGen Pharma Ltd, sale 7,379 shares at $11.14 during a trade that took place back on Jan 31 ’25, which means that Smith Jason Drew is holding 26,468 shares at $82,202 based on the most recent closing price.
Stock Fundamentals for URGN
Current profitability levels for the company are sitting at:
- -1.18 for the present operating margin
- 0.9 for the gross margin
The net margin for UroGen Pharma Ltd stands at -1.51. The total capital return value is set at -0.53.
Based on UroGen Pharma Ltd (URGN), the company’s capital structure generated 1.59 points at debt to capital in total, while cash flow to debt ratio is standing at -0.86. The debt to equity ratio resting at -2.69. The interest coverage ratio of the stock is -17.97.
Currently, EBITDA for the company is -110.33 million with net debt to EBITDA at -0.21. When we switch over and look at the enterprise to sales, we see a ratio of 3.9. The receivables turnover for the company is 4.68for trailing twelve months and the total asset turnover is 0.37. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.65.
Conclusion
In conclusion, UroGen Pharma Ltd (URGN) has had a bad performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
